유준환

Professional Experience

2002. 3 - 2003. 2       Internship, Ajou University Hospital, Suwon, Korea

2003. 3 - 2007. 2       Residency, Department of Internal Medicine, Ajou University Hospital, Suwon, Korea

2010.5 - 2014.8       Clinical fellowship (Clinical instructor), Department of Gastroenterology, Ajou University Hospital, Suwon, Korea

2012.7-2013.11 Postdoctoral scholar, Center for Inflammatory Bowel Diseases, Division of Digestive Diseases, David Geffen School of Medicine at UCLA, USA (PI: Charalabos Pothoulakis and Hon Wai Koon)

2013.9 Visiting researcher, Department of Pathobiology, Lerner Research Institute, Cleveland Clinic Foundation, USA (PI: Claudio Fiocchi)

2013.12-2014.6 Visiting assistant researcher, Center for Inflammatory Bowel Diseases, Division of Digestive Diseases, David Geffen School of Medicine at UCLA, USA (PI: Charalabos Pothoulakis and Hon Wai Koon)

2014. 9 - 2020.2       Assistant professor, Digestive Disease Center, CHA Bundang Medical Center, CHA University, Korea

2017.8 - 2019.7       Visiting Scientist, Hopkins Center for Epithelial Disorders, Division of Gastroenterology & Hepatology, Johns Hopkins University School of Medicine, USA (PI: Mark Donowitz)

2020. 3 - present      Associate professor, Digestive Disease Center, CHA Bundang Medical Center, CHA University, Korea

Main Scientific Publications

Fibrostenotic strictures in Crohn's Disease. Yoo JH (first and corresponding), Holubar S, Rieder F. Intestinal Research. 2020;18(4):379-401.

Umbilical cord/placenta-derived mesenchymal stem cells inhibit fibrogenic activation in human intestinal myofibroblasts via inhibition of myocardin-related transcription factor A. Choi YJ, Koo JB, Kim HY, Seo JW, Lee EJ, Kim WR, Cho JY, Hahm KB, Hong SP, Kim DH, Yoo JH (co-corresponding). Stem Cell Res Ther. 2019 Sep 23;10(1):291.

Intestinal enteroids/organoids: A novel platform for drug discovery in inflammatory bowel diseases. Yoo JH (first and corresponding), Donowitz M. World J Gastroenterol. 2019 Aug 14;25(30):4125-4147,

Periodontitis is associated with an increased risk for proximal colorectal neoplasms. Kim GW, Kim YS, Lee SH, Park SG, Kim DH, Cho JY, Hahm KB, Hong SP, Yoo JH (corresponding). Sci Rep. 2019 May 17;9(1):7528.

Anti-fibrogenic effect of PPAR-y agonists in human intestinal myofibroblasts. Koo JB, Nam MO, Jung Y, Yoo J, Kim DH, Kim G, Shin SJ, Lee KM, Hahm KB, Kim JW, Hong SP, Lee KJ, Yoo JH (co-corresponding). BMC Gastroenterol. 2017 Jun 7;17(1):73. doi: 10.1186/s512876-017-0627-4.

Organoid-based epithelial to mesenchymal transition (OEMT) model: from an intestinal fibrosis perspective. Hahn S, Nam MO, Noh JH, Lee DH, Han HW, Kim DH, Hahm KB, Hong SP, Yoo JH (co-corresponding), Yoo J. Sci Rep. 2017 May 26;7(1):2435. doi: 10.1038/s41598-017-02190-5.

Jun Hwan Yoo, Samantha Ho, Deanna Hoang-Yeon Tran, Michelle Cheng, Kyriaki Bakirtzi, Yuzu Kubota, Ryan Ichikawa, Bowei Su, Diana Hoang-Ngoc Tran, Tressia C. Hing, Irene Chang, David Q Shih, Richard E. Issacson, Richard L. Gallo, Claudio Fiocchi, Charalabos Pothoulakis, and Hon Wai Koon: Anti-fibrogenic effects of the anti-microbial peptide cathelicidin in murine colitis-associated fibrosis. Cellular and Molecular Gastroenterology and Hepatology 1(1): 55-74, Jan, 2015

Michelle Cheng, Samantha Ho, Jun Hwan Yoo (co-first author), Deanna Hoang-Yeon Tran, Kyriaki Bakirtzi, Bowei Su, Diana Hoang-Ngoc Tran, Yuzu Kubota, Ryan Ichikawa, and Hon Wai Koon: Cathelicidin suppresses colon cancer development by inhibition of cancer associated fibroblasts. Clinical and Experimental Gastroenterology 2015(8): 13- 29, Dec, 2014

연구 동기

Members

• 분당차병원 소화기내과 김지현 조교수
• 최윤정 박사
• 이동주 연구원
• 이연주 학생 (RECOMP)

소화기 기초/중개연구의 시작 story